Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on October 8, 2007
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hym103
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/10/744    most recent
hym103v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kim, S.-G.
Right arrow Articles by Kim, H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, S.-G.
Right arrow Articles by Kim, H.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 Foundation for Promotion of Cancer Research

A Phase II Study of Irinotecan with Bi-weekly, Low-dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFIRI) as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer

Seong-Geun Kim, Sung Yong Oh, Hyuk-Chan Kwon, Suee Lee, Jung Hwan Kim, Sung-Hyun Kim and Hyo-Jin Kim

Departments of Internal Medicine, Dong-A University College of Medicine, Busan, Korea

For reprints and all correspondence: Hyo-Jin Kim, Department of Internal Medicine, Dong-A University College of Medicine, 3-1 Dongdaeshin-dong, Seo-gu, Busan, 602-715, Korea. E-mail: kimhj{at}dau.ac.kr

Received April 22, 2007; accepted June 22, 2007

Objective: This phase II study was designed to assess the safety and efficacy of a modified FOLFIRI regimen (irinotecan with bi-weekly, low dose leucovorin (ldLV) and bolus and continuous infusion with 5-fluorouracil (5-FU)) as a salvage therapy for patients with advanced or metastatic gastric cancer.

Methods: Patients were treated with irinotecan 150 mg/m2 on day 1 and received ldLV 20 mg/m2 followed by 5-FU 400 mg/m2 (bolus) and 5-FU 600 mg/m2 (22 h continuous infusion) on days 1 and 2 every 14 days.

Results: A total of 36 patients were assigned to treatment. The median patient age was 55 years (range 31–70), and 55.6% (20/36) of the patients had performance status (ECOG) of 0 or 1.The median follow-up duration was 15.5 (range 2.6–36.4) months. Of the 30 patients evaluated for their tumor response, three achieved a partial response, with an overall response rate of 10.0% (95% CI 0.0–21.0%). Eleven patients (36.7%) showed stable disease. The median time to progression was 3.3 (95% CI 2.0–4.6) months, and the median overall survival time was 10.9 (95% CI 6.1–15.7) months. The median number of cycles of modified FOLFIRI treatment was 3 (range 1–9 cycles). Grade III or IV neutropenia was observed in 23 cycles (17.6%), and febrile neutropenia occurred in three cycles (2.3%). Grade III nausea/vomiting was found in one patient (2.8%). There was one episode of UGI bleeding, but there were no treatment-related deaths.

Conclusion: The modified FOLFIRI regimen described here appears a safe and feasible salvage therapy in advanced gastric cancer patients.

Key Words: irinotecan • low-dose leucovorin • 5-fluorouracil • advanced gastric cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
M.-D. Seo, K.-W. Lee, J. H. Lim, H. G. Yi, D.-Y. Kim, D.-Y. Oh, J. H. Kim, S.-A. Im, T.-Y. Kim, J. S. Lee, et al.
Irinotecan Combined with 5-Fluorouracil and Leucovorin as Second-line Chemotherapy for Metastatic or Relapsed Gastric Cancer
Jpn. J. Clin. Oncol., September 1, 2008; 38(9): 589 - 595.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.